Daily Respiratory Research Analysis
Three impactful studies in respiratory medicine stood out today: a phase 3 RCT showed adagrasib improves progression-free survival over docetaxel in previously treated KRAS-mutant NSCLC; a double-blind RCT in Asia confirmed tezepelumab markedly lowers exacerbations and improves lung function in severe, uncontrolled asthma across biomarker strata; and a longitudinal immunoepidemiological study demonstrated high post-NPI exposure to endemic respiratory viruses in U.S. children and showed that inte
Summary
Three impactful studies in respiratory medicine stood out today: a phase 3 RCT showed adagrasib improves progression-free survival over docetaxel in previously treated KRAS-mutant NSCLC; a double-blind RCT in Asia confirmed tezepelumab markedly lowers exacerbations and improves lung function in severe, uncontrolled asthma across biomarker strata; and a longitudinal immunoepidemiological study demonstrated high post-NPI exposure to endemic respiratory viruses in U.S. children and showed that integrating serology greatly improves forecasting of EV-D68 dynamics.
Research Themes
- Targeted therapy advances in KRAS-mutant NSCLC
- Type 2–epithelial cytokine pathway blockade for severe asthma
- Immunoepidemiological surveillance to forecast endemic respiratory viruses
Selected Articles
1. Adagrasib versus docetaxel in KRAS
In the multicenter, phase 3 KRYSTAL-12 trial, adagrasib significantly prolonged progression-free survival versus docetaxel in previously treated patients with KRAS-mutant NSCLC, with a hazard ratio of 0.58 and comparable rates of grade ≥3 treatment-related adverse events. Median PFS was 5.5 months with adagrasib versus 3.8 months with docetaxel.
Impact: This is a definitive phase 3 head-to-head comparison establishing a targeted therapy advantage over chemotherapy in KRAS-mutant NSCLC, a historically difficult-to-treat subset.
Clinical Implications: Adagrasib may become a preferred standard option over docetaxel for previously treated KRAS-mutant NSCLC, pending overall survival and quality-of-life data and access considerations.
Key Findings
- Median PFS: 5.5 months (adagrasib) vs 3.8 months (docetaxel); HR 0.58; p<0.0001.
- Grade ≥3 treatment-related adverse events: 47% (adagrasib) vs 46% (docetaxel).
- Treatment-related deaths: 1% in both arms (4 vs 1 patients, respectively).
Methodological Strengths
- Randomized, multicenter phase 3 design with ITT analysis
- Robust statistical significance for primary endpoint (PFS)
Limitations
- Open-label design may introduce bias in assessment of secondary outcomes
- Overall survival and long-term safety data not reported in the abstract
Future Directions: Assess overall survival, patient-reported outcomes, resistance mechanisms, and optimal sequencing with other targeted agents and immunotherapies.
BACKGROUND: Adagrasib is a KRAS METHODS: KRYSTAL-12 is a randomised, multicentre, open-label, phase 3 trial conducted at 230 centres in 22 countries. Patients with Kirsten rat sarcoma viral oncogene homologue (KRAS) FINDINGS: Between Feb 23, 2021, and Nov 16, 2023, 453 patients were randomly allocated to receive adagrasib (301 [66%]) or docetaxel (152 [34%]). In each group, 298 (99%) patients received adagrasib and 140 (92%) received docetaxel. In the ITT population (median follow-up 7·2 months [95% CI 5·8-8·7]), median progression-free survival was 5·5 months (95% CI 4·5-6·7) with adagrasib and 3·8 months (95% CI 2·7-4·7) with docetaxel (hazard ratio 0·58 [95% CI 0·45-0·76]; p<0·0001). Grade 3 and above treatment-related adverse events occurred in 140 (47%) of 298 patients treated with adagrasib and 64 (46%) of 140 with docetaxel. There were four (1%) treatment-related deaths in the adagrasib group and one (1%) treatment-related death in the docetaxel group. INTERPRETATION: Adagrasib demonstrated a statistically significant improvement in progression-free survival over docetaxel in patients with previously treated KRAS FUNDING: Mirati Therapeutics, a Bristol Myers Squibb company.
2. Efficacy and Safety of Tezepelumab in Adults With Severe, Uncontrolled Asthma in Asia: Results From the Phase 3 DIRECTION Study.
In the phase 3 DIRECTION trial across China, the Philippines, and Korea, tezepelumab reduced annualized asthma exacerbations by 74% versus placebo and improved pre-bronchodilator FEV1, asthma control, and HRQoL in adults with severe, uncontrolled asthma irrespective of baseline biomarkers. Benefits were also evident in patients with baseline blood eosinophils <300 cells/μL.
Impact: Provides robust, region-specific phase 3 evidence supporting tezepelumab across biomarker strata in Asian populations, aligning with and extending global findings.
Clinical Implications: Supports tezepelumab as a biomarker-agnostic add-on biologic for severe, uncontrolled asthma in Asian adults, including those with lower eosinophil counts.
Key Findings
- Annualized exacerbation rate reduced by 74% vs placebo overall (95% CI: 61, 83; P<.001).
- Exacerbations reduced by 60% in patients with baseline blood eosinophils <300 cells/μL.
- Improved pre-bronchodilator FEV1, asthma control, and HRQoL at 52 weeks.
Methodological Strengths
- Multicenter, double-blind randomized design with 52-week follow-up
- No biomarker restrictions, enhancing generalizability
Limitations
- Geographic focus limited to three Asian countries
- Long-term safety and durability beyond 52 weeks not detailed in the abstract
Future Directions: Evaluate long-term safety, exacerbation prevention durability, steroid-sparing effects, and comparative effectiveness versus other biologics across diverse Asian subpopulations.
BACKGROUND: Tezepelumab, a human monoclonal antibody that blocks thymic stromal lymphopoietin, reduced the annualized asthma exacerbation rate (AAER) and improved lung function, asthma control, and health-related quality of life (HRQoL) in patients with severe, uncontrolled asthma (SUA) in the global, phase 3 NAVIGATOR study (NCT03347279). OBJECTIVE: DIRECTION was a phase 3, multicenter, double-blind study that assessed the efficacy and safety of tezepelumab in adults with SUA in China, the Philippines, and the Republic of Korea. METHODS: Patients (18-80 years old) with SUA (no baseline biomarker restrictions) were randomized 1:1 to receive tezepelumab 210 mg or placebo subcutaneously every 4 weeks for 52 weeks. The primary end point was the AAER over 52 weeks. Key secondary end points were changes from baseline to week 52 in prebronchodilator forced expiratory volume in 1 second (FEV RESULTS: Overall, 400 patients received tezepelumab (n = 201) or placebo (n = 199). Tezepelumab significantly reduced AAERs versus placebo by 74% (95% confidence interval [CI]: 61, 83; P < .001) in the overall population and by 60% (95% CI: 31, 77) in patients with baseline blood eosinophil count <300 cells/μL. Tezepelumab significantly improved prebronchodilator FEV CONCLUSIONS: Tezepelumab reduced exacerbations and improved lung function, asthma control, and HRQoL in Asian patients with SUA, consistent with prior study findings.
3. Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022-23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study.
This prospective, multicenter immunoepidemiological study of 174 U.S. children documented high post-NPI exposure to multiple endemic respiratory viruses and demonstrated that incorporating EV-D68 serology into models substantially improved forecasting accuracy. Younger children showed the largest increases in antibody titres, and EV-D68 clade B3 predominated among sequenced respiratory samples.
Impact: Demonstrates the value of integrating serology with surveillance and modeling to anticipate pediatric respiratory virus waves, informing preparedness and countermeasure development.
Clinical Implications: Supports immunoepidemiological surveillance to inform timing of public health interventions, diagnostics, and resource allocation for pediatric respiratory seasons.
Key Findings
- High exposure rates between 2022 and 2023: SARS-CoV-2 59%, EV-D68 41%, RSV 41%, influenza 40% among paired sera.
- Respiratory swab sequencing frequently detected EV-D68 (clade B3), rhinovirus A, and rhinovirus C.
- Adding EV-D68 serology to models reduced the range of prediction errors by 82% and median errors by 33% compared with surveillance alone.
Methodological Strengths
- Prospective, multicenter design with longitudinal paired serology and neutralization validation
- Integration of metagenomic sequencing with epidemiological modeling
Limitations
- Modest cohort size with attrition; only 90 paired sera analyzed
- Three-site U.S. sampling may limit generalizability to other settings
Future Directions: Scale immunoepidemiological platforms, expand age and geographic coverage, and assess how serology-driven forecasts optimize timing of vaccines, monoclonals, and hospital readiness.
BACKGROUND: The Pandemic Response Repository through Microbial and Immune Surveillance and Epidemiology (PREMISE) programme was established to translate knowledge gained from global immunoepidemiological surveillance into a better understanding of population-level dynamics of emerging and re-emerging infections, as well as into the discovery and development of biomedical countermeasures against potential pandemic threats. As proof of principle for this approach, we conducted a longitudinal immunoepidemiological study in children in the USA, focusing on enterovirus D68 (EV-D68) infection dynamics but also capturing surveillance of a broad array of other endemic respiratory pathogens. Serendipitously, our sampling spanned the lifting of widespread COVID-19 non-pharmaceutical interventions (NPIs) in 2022-23, following a unique period during which virus exposure markedly diminished. METHODS: This prospective, multicentre, longitudinal, immunoepidemiological surveillance study enrolled children aged 10 years or younger and weighing at least 8 kg at three US university sites. Blood specimens collected from January to June, 2022 (visit 1; pre-enterovirus season), and from January to June, 2023 (visit 3; post-enterovirus season), were tested in a multiplex assay for antibody binding to EV-D68 (prespecified primary objective) and a panel of 15 other respiratory viruses (exploratory objectives), and for neutralising activity against EV-D68, enterovirus A71, and respiratory syncytial virus (RSV; for antibody binding assay validation). Respiratory mid-turbinate swabs collected from children with symptomatic illness who participated in symptom surveys during July-December, 2022 (visit 2; enterovirus season), underwent metagenomic sequencing for pathogen detection. Serological data for EV-D68 were incorporated into epidemiological models based on case data from national surveillance to predict future transmission dynamics. FINDINGS: Of 488 eligible children approached, 174, with a median age of 3·4 years (IQR 1·9-6·4), were enrolled and followed up longitudinally from January, 2022, to June, 2023. Three children withdrew before study completion and 51 were lost to follow-up between visits 1 and 3. 90 paired serological samples and 73 respiratory swabs were tested. Mean antibody binding and neutralisation titres against all viruses tested increased over the study period, most notably in younger children with lower initial titres. The highest exposure rates (seroconversion or antibody boosting) were seen with SARS-CoV-2 (51 [59%] of 87), EV-D68 (36 [41%] of 87), RSV (36 [41%] of 87), and influenza (35 [40%] of 87), whereas the pathogens most frequently detected by respiratory swab sequencing were EV-D68 (clade B3), rhinovirus A, and rhinovirus C (n=7 each). Incorporating EV-D68 serological data into epidemiological models resulted in an 82% reduction in the range of prediction errors and a 33% reduction in median prediction errors for longer-term EV-D68 circulation dynamics compared with national pathogen surveillance data alone. INTERPRETATION: In this study, we captured immunological evidence of endemic virus re-emergence in children following lifting of pandemic NPIs, which revealed high rates of exposure to endemic respiratory pathogens in a large group of seronegative, predominantly younger, children. This study demonstrates the feasibility and utility of immunoepidemiological surveillance to enable more precise and accurate modelling of pathogen circulation dynamics to predict and prepare for future waves of disease. FUNDING: Intramural Research Program of the National Institute of Allergy and Infectious Diseases-Vaccine Research Center, and the National Cancer Institute, National Institutes of Health.